SIGA shares shoot up on potential US biodefence contract
This article was originally published in Scrip
Shares of biodefence company SIGA Technologies closed 46% up at $12.47 (13 October) on news that the US Department of Health and Human Services (HHS) intends to award it a contract worth up to $2.8 billion for the delivery of 1.7 million courses of its smallpox vaccine for the strategic national stockpile.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.